OBJECTIVE: Previous studies have suggested that delayed gastric emptying and abnormal postprandial release of hormones that influence satiation, particularly cholecystokinin (CCK), may play an important role in the pathophysiology of bulimia nervosa (BN). This study was designed to test these hypotheses as well as the efficacy of the prokinetic agent erythromycin in patients with BN. METHOD: Thirty-two normal-weight women with BN and 24 control participants consumed alarge liquid test meal. Gastric emptying and pre- and postprandial release of CCK, peptide YY (PYY), and ghrelin were determined. Participants with BN were then recruited for double-blind treatment with erythromycin up to 500 mg three times daily vs. placebo for 6 weeks, following which they consumed a repeat test meal with gastric emptying and appetitive hormone measurements. RESULTS:CCK release at 15 min following the meal was marginally lower (p=0.1) in BN than in control participants. Rate of gastric emptying and postprandial hormone release were similar in BN and controls. BN patients assigned to erythromycin compared to those assigned to placebo had more rapid gastric emptying following treatment, but there were no differences in release of CCK, PYY, or ghrelin following the post-treatment test meal. Moreover, treatment with erythromycin was not associated with clinical response. DISCUSSION: The current study does not support the clinical utility of moderate dose erythromycin in treating BN. Furthermore, the findings suggest that a modest increase in gastric emptying rate is associated neither with altered postprandial hormonal release nor with clinical benefit in these patients. While providing no evidence for the effectiveness of prokinetic agents in this setting, our findings do not preclude the possibility that a greater increase in gastric emptying rate might prove beneficial.
RCT Entities:
OBJECTIVE: Previous studies have suggested that delayed gastric emptying and abnormal postprandial release of hormones that influence satiation, particularly cholecystokinin (CCK), may play an important role in the pathophysiology of bulimia nervosa (BN). This study was designed to test these hypotheses as well as the efficacy of the prokinetic agent erythromycin in patients with BN. METHOD: Thirty-two normal-weight women with BN and 24 control participants consumed a large liquid test meal. Gastric emptying and pre- and postprandial release of CCK, peptide YY (PYY), and ghrelin were determined. Participants with BN were then recruited for double-blind treatment with erythromycin up to 500 mg three times daily vs. placebo for 6 weeks, following which they consumed a repeat test meal with gastric emptying and appetitive hormone measurements. RESULTS:CCK release at 15 min following the meal was marginally lower (p=0.1) in BN than in control participants. Rate of gastric emptying and postprandial hormone release were similar in BN and controls. BN patients assigned to erythromycin compared to those assigned to placebo had more rapid gastric emptying following treatment, but there were no differences in release of CCK, PYY, or ghrelin following the post-treatment test meal. Moreover, treatment with erythromycin was not associated with clinical response. DISCUSSION: The current study does not support the clinical utility of moderate dose erythromycin in treating BN. Furthermore, the findings suggest that a modest increase in gastric emptying rate is associated neither with altered postprandial hormonal release nor with clinical benefit in these patients. While providing no evidence for the effectiveness of prokinetic agents in this setting, our findings do not preclude the possibility that a greater increase in gastric emptying rate might prove beneficial.
Authors: S Fujimoto; A Inui; N Kiyota; W Seki; K Koide; S Takamiya; M Uemoto; Y Nakajima; S Baba; M Kasuga Journal: Biol Psychiatry Date: 1997-05-15 Impact factor: 13.382
Authors: M Höcker; W E Schmidt; H M Wilms; F Lehnhoff; R Nustede; A Schafmayer; U R Fölsch Journal: Eur J Clin Invest Date: 1990-10 Impact factor: 4.686
Authors: Laura A Berner; Tiffany A Brown; Jason M Lavender; Emily Lopez; Christina E Wierenga; Walter H Kaye Journal: Mol Cell Endocrinol Date: 2018-11-02 Impact factor: 4.102
Authors: Michael Camilleri; Henry P Parkman; Mehnaz A Shafi; Thomas L Abell; Lauren Gerson Journal: Am J Gastroenterol Date: 2012-11-13 Impact factor: 10.864
Authors: Caroline Riedlinger; Greta Schmidt; Alisa Weiland; Andreas Stengel; Katrin Elisabeth Giel; Stephan Zipfel; Paul Enck; Isabelle Mack Journal: Front Psychiatry Date: 2020-04-20 Impact factor: 4.157
Authors: Kvido Smitka; Hana Papezova; Karel Vondra; Martin Hill; Vojtech Hainer; Jara Nedvidkova Journal: Int J Endocrinol Date: 2013-09-09 Impact factor: 3.257